{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T21:41:30Z","timestamp":1771623690517,"version":"3.50.1"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Vedolizumab is a gut selective anti-integrin monoclonal antibody with a very good and proven safety profile in the treatment of ulcerative colitis (UC). This case report highlights a rather unusual complication that every gastroenterologist ought to be aware of. It relates to the association of acute interstitial nephritis with vedolizumab usage in the management of UC. A 53-year-old man with liver cirrhosis due to Primary Sclerosing Cholangitis and UC was treated with vedolizumab following failed therapy with thiopurines and mesalazine. This led to improvement in his bowel function but his renal function steadily declined over subsequent months, in the presence of reactive urinary sediments. A subsequent renal biopsy demonstrated acute interstitial nephritis. Cessation of vedolizumab, along with high dose steroids treatment, led to near complete resolution of his renal failure.<\/jats:p>","DOI":"10.1093\/omcr\/omaf148","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T11:18:35Z","timestamp":1753096715000},"source":"Crossref","is-referenced-by-count":1,"title":["Vedolizumab induced acute interstitial nephritis"],"prefix":"10.1093","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8697-920X","authenticated-orcid":false,"given":"Darren","family":"Fernandes","sequence":"first","affiliation":[{"name":"The Department of Gastroenterology, Nottingham Digestive Diseases Centre , Derby Road, Nottingham, NG7 2UH ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alok","family":"Mathew","sequence":"additional","affiliation":[{"name":"The Department of Gastroenterology, Nottingham Digestive Diseases Centre , Derby Road, Nottingham, NG7 2UH ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alastair","family":"Ferraro","sequence":"additional","affiliation":[{"name":"Renal and Transplant Unit, Nottingham University Hospitals , Hucknall Road, Nottingham, NG5 1PB ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Samuel","sequence":"additional","affiliation":[{"name":"The Department of Gastroenterology, Nottingham Digestive Diseases Centre , Derby Road, Nottingham, NG7 2UH ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"2026012811460511800_ref1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","article-title":"Optimizing anti-TNF treatments in inflammatory bowel disease","volume":"13","author":"Ben-Horin","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2026012811460511800_ref2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/apt.13445","article-title":"Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management","volume":"43","author":"Ding","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2026012811460511800_ref3","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/ajg.2008.88","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"2026012811460511800_ref4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/MIB.0000000000000202","article-title":"Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse","volume":"21","author":"Papamichael","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2026012811460511800_ref5","doi-asserted-by":"publisher","first-page":"e00788","DOI":"10.14309\/crj.0000000000000788","article-title":"Vedolizumab-induced acute interstitial nephritis in ulcerative colitis","volume":"9","author":"Subhaharan","year":"2022","journal-title":"ACG Case Rep J"},{"key":"2026012811460511800_ref6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/apt.15921","article-title":"Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease","volume":"52","author":"Bohm","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2026012811460511800_ref7","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/00365521.2024.2345383","article-title":"Acute interstitial nephritis in patients with inflammatory bowel disease treated with vedolizumab: a systematic review","volume":"59","author":"Forss","year":"2024","journal-title":"Scand J Gastroenterol"},{"key":"2026012811460511800_ref8","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.2215\/CJN.07630717","article-title":"Drug-induced acute interstitial nephritis","volume":"12","author":"Moledina","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026012811460511800_ref9","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/ki.2010.89","article-title":"Acute interstitial nephritis","volume":"77","author":"Praga","year":"2010","journal-title":"Kidney Int"},{"key":"2026012811460511800_ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-243568","article-title":"Acute interstitial nephritis secondary to vedolizumab","volume":"14:","author":"Simpson","year":"2021","journal-title":"BMJ Case Rep"},{"key":"2026012811460511800_ref11","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/sj.ki.5002776","article-title":"Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis","volume":"73","author":"Gonzalez","year":"2008","journal-title":"Kidney Int"},{"key":"2026012811460511800_ref12","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2023-254715","article-title":"Vedolizumab-induced acute interstitial nephritis with failure of steroid prophylaxis on vedolizumab rechallenge","volume":"16","author":"O'Leary","year":"2023","journal-title":"BMJ Case Rep"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2026\/1\/omaf148\/66612933\/omaf148.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2026\/1\/omaf148\/66612933\/omaf148.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T16:46:13Z","timestamp":1769618773000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omaf148\/8443410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,24]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omaf148","relation":{},"ISSN":["2053-8855"],"issn-type":[{"value":"2053-8855","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"omaf148"}}